Cargando…
Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242718/ https://www.ncbi.nlm.nih.gov/pubmed/34032357 http://dx.doi.org/10.1111/jcmm.16565 |
| _version_ | 1783715648012025856 |
|---|---|
| author | Agrati, Chiara Castilletti, Concetta Sacchi, Alessandra Colavita, Francesca Capobianchi, Maria Rosaria Puro, Vincenzo Nicastri, Emanuele Ippolito, Giuseppe Bibas, Michele |
| author_facet | Agrati, Chiara Castilletti, Concetta Sacchi, Alessandra Colavita, Francesca Capobianchi, Maria Rosaria Puro, Vincenzo Nicastri, Emanuele Ippolito, Giuseppe Bibas, Michele |
| author_sort | Agrati, Chiara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8242718 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82427182021-07-01 Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient Agrati, Chiara Castilletti, Concetta Sacchi, Alessandra Colavita, Francesca Capobianchi, Maria Rosaria Puro, Vincenzo Nicastri, Emanuele Ippolito, Giuseppe Bibas, Michele J Cell Mol Med Letter to the Editor John Wiley and Sons Inc. 2021-05-25 2021-07 /pmc/articles/PMC8242718/ /pubmed/34032357 http://dx.doi.org/10.1111/jcmm.16565 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Agrati, Chiara Castilletti, Concetta Sacchi, Alessandra Colavita, Francesca Capobianchi, Maria Rosaria Puro, Vincenzo Nicastri, Emanuele Ippolito, Giuseppe Bibas, Michele Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient |
| title | Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient |
| title_full | Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient |
| title_fullStr | Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient |
| title_full_unstemmed | Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient |
| title_short | Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient |
| title_sort | immunogenicity and safety of bnt162b2 covid‐19 vaccine in a chronic lymphocytic leukaemia patient |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242718/ https://www.ncbi.nlm.nih.gov/pubmed/34032357 http://dx.doi.org/10.1111/jcmm.16565 |
| work_keys_str_mv | AT agratichiara immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT castilletticoncetta immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT sacchialessandra immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT colavitafrancesca immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT capobianchimariarosaria immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT purovincenzo immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT nicastriemanuele immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT ippolitogiuseppe immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient AT bibasmichele immunogenicityandsafetyofbnt162b2covid19vaccineinachroniclymphocyticleukaemiapatient |